Oxidative phosphorylation inhibition with IACS-010759 treatment in colorectal cancer cells
Although targeting oxidative phosphorylation (OXPHOS) in cancer is currently impeded due to dose-limiting toxicities, there remain opportunities through combination treatments that provide therapeutic benefits at doses attainable in patients. While glycolysis-deficient cancers are generally vulnerable to OXPHOS inhibition in preclinical models, the full extent of phenotypical and mechanistic consequences of inhibiting OXPHOS in cancers capable of glycolysis is not yet well understood. We aimed to clarify the response and underlying mechanisms of glycolysis-competent colorectal cancer (CRC) to OXPHOS inhibition and to identify potential approaches to render such cells more sensitive to OXPHOS inhibitors. Overall design: To investigate the mechanisms of CRC cells response to OXPHOS inhibition, we treated LIM1215 and Colo205 with OXPHOS inhibitor IACS-010759 (IACS) at 100 nM for 24 hours. Cells treated with DMSO was set as control. Each sample has duplicate repeat.